GLUCOR
50 MG · tablet · box of 30
ACARBOSEHistorical reference: this presentation is not marketed, withdrawn or suspended according to the source. Its listed price does not establish availability.
Reference dated : 2026-06-01. Confirm price and availability with a pharmacist.
Public price
49,70 MAD
Laboratory
BAYER S.A
What is this medicine?
French reference leaflet: ACARBOSE VIATRIS 50 mg, comprimé. Confirm indications in Morocco with a pharmacist.
Pharmacotherapeutic class: alpha-glucosidase inhibitors - ATC code: A 1 0BF01 ACARBOSE VIATRIS is an antidiabetic. It delays the digestion and absorption of sugars by the intestine. Its action delays the passage of sugar into the blood, thereby decreasing the rise in blood sugar levels that occurs after a meal. In which cases is it used? This medicine is used to treat a certain form of diabetes called "type 2 diabetes" (or non-insulin-dependent diabetes), in conjunction with diet. It is reserved for adults. The efficacy and tolerability of ACARBOSE VIATRIS have not been established in children under 18 years of age.
Full clinical reference
Additional sections are available in French. Read the original document; the information concerns the French reference product.
Uses
Treatment of non-insulin-dependent diabetes, as an adjunct to diet, as monotherapy or in combination with other antidiabetic therapies.
Pregnancy and breastfeeding
Pregnancy
Risk related to diabetes
Diabetes (gestational or permanent), when not balanced, is the cause of an increase in congenital malformations and perinatal mortality. In the periconceptional period, as good a balance of diabetes as possible must be achieved, in order to reduce the malformation risk.
Risk related to acarbose
Animal studies have not demonstrated any teratogenic effect. In the absence of a teratogenic effect in animals, a malformation effect in the human species is not expected.
Indeed, to date, substances responsible for malformations in the human species have proven to be teratogenic in animals during well-conducted studies on two species.
Clinically, there is currently no sufficiently relevant data on a possible malformation or foetotoxic effect of acarbose when administered during pregnancy.
Management
Rebalancing diabetes allows for normalizing the course of pregnancy in this category of patients.
It imperatively requires insulin, regardless of the type of diabetes, I or II, gestational or permanent.
In the latter case, it is recommended to stop treatment with acarbose and to take over with insulin as soon as a pregnancy is envisaged or in case of fortuitous discovery of a pregnancy exposed to this medicine: in this case, this does not constitute the systematic argument to advise an interruption of pregnancy but leads to a cautious attitude and to oriented prenatal surveillance.
Neonatal blood glucose monitoring is recommended
Breastfeeding
After administration of radiolabelled acarbose in the lactating rat, a small amount was detected in the milk. To date, there is no similar data in humans.
However, as the risk of acarbose effects on the breastfed child cannot be excluded, this medicine is not recommended in case of breastfeeding.
Driving
No data is available on the effects of treatment with acarbose on the ability to drive vehicles and use machines.
Hospital price
31,10 MAD
Commercial status
Non Commercialisé
References and update dates
Historical reference; confirm the price with a pharmacist.
Base de données publique des médicaments (France) · 2026-09-29 · Licence Ouverte
Read medical referenceThis information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2026-06-01: 49,70 MAD
Referenced presentations and strengths
Same ingredient, strength and form
This grouping does not establish interchangeability.
Other strengths and forms
Routes and instructions may differ.